Daniel on for Vijay Kumar's questions to OraSure Technologies Inc (OSUR) leadership • Q4 2024
Question
Daniel, on behalf of Vijay Kumar, asked about the dynamics of the consumer genomics customer timing issue in Q1, questioning if it reflects broader market softness. He also asked for a framework on the potential long-term downside from international government-funded markets beyond Q1.
Answer
President and CEO Carrie Eglinton Manner clarified the Q1 issue relates to a single large customer's specific strategic process, not broader market softness, and highlighted the company's successful diversification into clinical diagnostics, pharma, and animal health. Regarding long-term international risk, she emphasized the durability of multilateral, multi-country donor funding for public health initiatives like HIV testing, which constitutes a large portion of the business, expressing confidence despite near-term uncertainty.